|
業務類別
|
Biotechnology |
|
業務概覽
|
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases. |
| 公司地址
| 264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000 |
| 電話號碼
| +61 283157003 |
| 傳真號碼
| +61 285691880 |
| 公司網頁
| https://www.immutep.com |
| 員工數量
| 44 |
| Mr. Christian Mueller |
Chief Development Officer |
美元 303.61K |
24/10/2025 |
| Dr. Stephan Winckels, M.D.,PhD |
Chief Medical Officer |
-- |
24/10/2025 |
| Mr. Marc Voigt |
Director, Chief Executive Officer and Chief Financial Officer |
-- |
24/10/2025 |
| Ms. Deanne Miller |
Chief Operating Officer, General Counsel and Company Secretary |
澳元 300.04K |
24/10/2025 |
| Professor Dr. Frederic Triebel, M.D. |
Executive Director and Chief Scientific Officer |
-- |
24/10/2025 |
|
|
| Dr. Russell J. Howard, PhD |
Chairman of the Board |
24/10/2025 |
| Mr. Marc Voigt |
Director, Chief Executive Officer and Chief Financial Officer |
24/10/2025 |
| Mr. Pete A. Meyers |
Deputy Chairman of the Board |
24/10/2025 |
| Professor Dr. Frederic Triebel, M.D. |
Executive Director and Chief Scientific Officer |
24/10/2025 |
| Ms. Lis Boyce |
Independent Director |
24/10/2025 |
|
|
|
|
